An Exploratory Study to Evaluate Efficacy and Safety of Fruquintinib as Second-line Treatment for Patients With Advanced or Metastatic Biliary Tract Cancer
Latest Information Update: 06 Jul 2023
Price :
$35 *
At a glance
- Drugs Fruquintinib (Primary)
- Indications Adenocarcinoma; Biliary cancer
- Focus Therapeutic Use
- Acronyms FSTAMBTA
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Status changed from not yet recruiting to recruiting as per trial design presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Trial design presented at the 56th Annual Meeting of the American Society of Clinical Oncology